Zacks Research Estimates Editas Medicine FY2027 Earnings

Editas Medicine, Inc. (NASDAQ:EDIT) – Equities research analysts at Zacks Research issued their FY2027 earnings per share (EPS) estimates for Editas Medicine in a report issued on Wednesday, March 26th. Zacks Research analyst A. Chakraborty forecasts that the company will post earnings per share of ($2.30) for the year. The consensus estimate for Editas Medicine’s current full-year earnings is ($2.71) per share.

Several other equities research analysts also recently commented on the company. Evercore ISI reduced their price objective on Editas Medicine from $7.00 to $5.00 and set an “outperform” rating for the company in a report on Monday, December 16th. Stifel Nicolaus lowered shares of Editas Medicine from a “buy” rating to a “hold” rating and reduced their price target for the stock from $11.00 to $3.00 in a research note on Friday, December 13th. JPMorgan Chase & Co. cut shares of Editas Medicine from a “neutral” rating to an “underweight” rating in a report on Monday, December 16th. Chardan Capital reaffirmed a “neutral” rating on shares of Editas Medicine in a research report on Friday, December 13th. Finally, Royal Bank of Canada decreased their target price on shares of Editas Medicine from $5.00 to $4.00 and set a “sector perform” rating for the company in a research note on Friday, December 13th. Three analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $6.83.

Editas Medicine Trading Down 3.8 %

Shares of EDIT opened at $1.25 on Friday. The company has a market cap of $103.72 million, a price-to-earnings ratio of -0.49 and a beta of 1.88. The business’s fifty day simple moving average is $1.51 and its two-hundred day simple moving average is $2.17. Editas Medicine has a 12 month low of $1.12 and a 12 month high of $7.41.

Editas Medicine (NASDAQ:EDIT) last issued its earnings results on Wednesday, March 5th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.16). Editas Medicine had a negative return on equity of 80.13% and a negative net margin of 340.96%. The firm had revenue of $30.60 million during the quarter, compared to analysts’ expectations of $37.17 million. During the same period last year, the firm posted ($0.23) earnings per share.

Institutional Trading of Editas Medicine

A number of institutional investors and hedge funds have recently bought and sold shares of EDIT. Two Sigma Advisers LP increased its stake in Editas Medicine by 46.8% in the 4th quarter. Two Sigma Advisers LP now owns 1,657,000 shares of the company’s stock worth $2,104,000 after acquiring an additional 528,000 shares during the last quarter. Two Sigma Investments LP increased its holdings in shares of Editas Medicine by 21.4% in the 4th quarter. Two Sigma Investments LP now owns 1,649,072 shares of the company’s stock worth $2,094,000 after buying an additional 290,483 shares during the last quarter. Renaissance Technologies LLC bought a new position in shares of Editas Medicine in the 4th quarter valued at about $1,843,000. Balyasny Asset Management L.P. lifted its stake in shares of Editas Medicine by 647.3% in the 4th quarter. Balyasny Asset Management L.P. now owns 1,300,604 shares of the company’s stock valued at $1,652,000 after purchasing an additional 1,126,569 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Editas Medicine by 30.4% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,170,000 shares of the company’s stock worth $1,486,000 after buying an additional 272,467 shares during the period. 71.90% of the stock is currently owned by institutional investors.

Editas Medicine Company Profile

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.